Stockscreener 앱 받기
16.02
2.02%
-0.33
시간 외 거래:
16.06
0.04
+0.25%
전일 마감가:
$16.35
열려 있는:
$16.57
하루 거래량:
1.37M
Relative Volume:
0.99
시가총액:
$842.10M
수익:
$59,000
순이익/손실:
$-78.26M
주가수익비율:
-2.6278
EPS:
-6.0964
순현금흐름:
$-51.46M
1주 성능:
-1.54%
1개월 성능:
+15.09%
6개월 성능:
-13.64%
1년 성능:
+327.20%
1일 변동 폭
$15.90
$16.57
1주일 범위
$15.90
$17.10
52주 변동 폭
$3.4313
$24.27
아발로 테라퓨틱스 Stock (AVTX) Company Profile
명칭
Avalo Therapeutics Inc
전화
410-522-8707
주소
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
16.02 | 859.45M | 59,000 | -78.26M | -51.46M | -6.0964 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
아발로 테라퓨틱스 Stock (AVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-09 | 개시 | Wolfe Research | Outperform |
| 2026-04-06 | 개시 | Citizens | Mkt Outperform |
| 2026-02-02 | 개시 | Guggenheim | Buy |
| 2025-12-18 | 개시 | Mizuho | Outperform |
| 2025-09-17 | 재확인 | H.C. Wainwright | Buy |
| 2025-09-05 | 개시 | TD Cowen | Buy |
| 2025-08-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-02 | 재개 | H.C. Wainwright | Buy |
| 2025-03-25 | 개시 | Jefferies | Buy |
| 2025-03-25 | 개시 | Stifel | Buy |
| 2025-02-28 | 개시 | Piper Sandler | Overweight |
| 2025-02-21 | 개시 | Wedbush | Outperform |
| 2024-12-19 | 개시 | BTIG Research | Buy |
| 2024-10-24 | 개시 | H.C. Wainwright | Neutral |
| 2024-04-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-09-24 | 개시 | RBC Capital Mkts | Outperform |
모두보기
아발로 테라퓨틱스 주식(AVTX)의 최신 뉴스
Point72 (AVTX) reports 2.71M-share, 5.2% position in Avalo Therapeutics - Stock Titan
Avalo Therapeutics (AVTX) CSO granted 34,200 performance stock units vesting in 2028 - Stock Titan
Avalo Therapeutics (AVTX) CFO receives 39,900 PSU-linked shares in equity award - Stock Titan
Avalo Therapeutics (AVTX) CLO granted 24,300 performance-based common shares - Stock Titan
Avalo Therapeutics (AVTX) CMO receives 43,500-share performance award - Stock Titan
Performance stock units expand Avalo (NASDAQ: AVTX) CEO’s stake - Stock Titan
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Avalo Therapeutics (AVTX) CMO exercises options and sells 3,000 shares under plan - Stock Titan
Avalo Therapeutics (AVTX) price target increased by 18.49% to 47.94 - MSN
UBS Group AG Has $8.68 Million Stock Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty - TipRanks
Wolfe Research initiates coverage of Avalo Therapeutics (AVTX) with outperform recommendation - MSN
Logos Global (AVTX) discloses 1.675M-share position, 3.2% of stock - Stock Titan
Avalo Therapeutics stock soars after positive LOTUS trial results - MSN
RA Capital and principals report 9.99% stake in Avalo Therapeutics (AVTX) - Stock Titan
OrbiMed reports 475,165 Avalo Therapeutics shares (AVTX) at 2.1% - Stock Titan
BVF affiliates report ~2.35M AVTX shares (NYSE: AVTX) under group attribution - Stock Titan
A Quick Look at Today's Ratings for Avalo Therapeutics(AVTX.US), With a Forecast Between $34 to $55 - Moomoo
Caligan Partners and David Johnson report 7.2% stake in Avalo (AVTX) - Stock Titan
T. Rowe Price (AVTX) shows 2.16M shares, 9.5% of Avalo Therapeutics - Stock Titan
Avoro holds 1.41M shares in Avalo Therapeutics (NASDAQ: AVTX) - Stock Titan
These Analysts Revise Their Forecasts On Avalo Therapeutics After Q1 Results - Sahm
Apple To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm
Avalo Therapeutics stock jumps 33% in pre-market session: Here's why - MSN
Wedbush Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Raises Target Price to $34 - Moomoo
AVTX Maintains by Citizens -- Price Target Lowered to $55.00 - GuruFocus
AVTX Maintained by Mizuho -- Price Target Raised to $45.00 - GuruFocus
Affinity Asset Advisors discloses 5.5% stake in Avalo Therapeutics (NASDAQ: AVTX) - Stock Titan
AVTX Maintained by Wedbush -- Price Target Lowered to $34.00 - GuruFocus
AVTX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Mizuho Adjusts Price Target on Avalo Therapeutics to $45 From $39, Maintains Outperform Rating - Moomoo
Citizens Jmp Cuts Avalo Therapeutics (NASDAQ:AVTX) Price Target to $55.00 - MarketBeat
Wedbush Adjusts Price Target on Avalo Therapeutics to $34 From $40, Maintains Outperform Rating - Moomoo
A Quick Look at Today's Ratings for Avalo Therapeutics(AVTX.US), With a Forecast Between $34 to $58 - Moomoo
H.C. Wainwright cuts Avalo Therapeutics price target to $35 on trial data - Investing.com UK
Avalo Therapeutics (NASDAQ:AVTX) Price Target Cut to $35.00 by Analysts at HC Wainwright - MarketBeat
H.C. Wainwright cuts Avalo Therapeutics price target to $35 on trial data By Investing.com - Investing.com South Africa
Citizens cuts Avalo Therapeutics stock price target on equity financing - Investing.com UK
Citizens cuts Avalo Therapeutics stock price target on equity financing By Investing.com - Investing.com Australia
AVTX SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Avalo Therapeutics, Inc. Stock 12‑Month Price Target Cut to $47.27, Implies 137% Upside - TradingView
Avalo Therapeutics, Inc. Stock 12‑Month Price Target Cut to $47.82, Implies 140% Upside - TradingView
Avalon (AVTX) Reports Promising Trial Results for Abdakibart in HS Treatment - GuruFocus
Avalo Therapeutics Q1 Net Loss Narrows - Moomoo
Avalo Therapeutics, Inc. Q1 2026 10-Q Report: Financial Statements, Results, and SEC Filings Overview - Minichart
Avalo Therapeutics, Inc. Stock 12‑Month Price Target Raised to $48.7, Implies 144% Upside - TradingView
Avalo Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Avalo Therapeutics Reports Positive Phase 2 Results for Abdakibart in Hidradenitis Suppurativa and Raises $431M to Fund Phase 3 Trial - Minichart
Is Avalo Therapeutics (AVTX) Overvalued After Q1 2026 EPS Beat? - GuruFocus
아발로 테라퓨틱스 (AVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):